title: Local hyperthermia and systemic chemotherapy for treatment of recurrent melanoma.
abstract: Thirty-two patients with recurrent (skin) or metastatic (skin, node, or both) melanoma have been treated with a hyperthermia-cisplatin regimen. The hyperthermic treatment was carried out for 60 minutes at 43 degrees C with the MHS-SMA and the Sapic SVO3 ALENIA devices once a week. When the tumor temperature reached 42 degrees C, cisplatin was administered at a dosage of 50 mg/m2 given by intravenous bolus infusion. The treatment was repeated four times and the tumor response evaluated 4 weeks after the last treatment. Significant systemic or local toxicity was not seen. In terms of results, there were 9 patients with complete responses (28.1%), 13 with partial responses (40.6%), 8 with no change (25.0%), and two with disease progression (6.3%). The objective response rate was 68.7%. The response duration for those with complete responses ranged from 4 to 49 months (median 20 months). The median time to progression for patients with partial responses and those with no change was 6 and 5 months, respectively, with ranges of 1-7 and 1-10 months, respectively. The 4-year actuarial survival rates were 47.6% and 20.3% for the complete and incomplete responders, respectively. These results can be considered satisfactory, taking into account that most patients were pretreated with radiotherapy, chemotherapy or both, confirming the therapeutic potential of the hyperthermia and cisplatin regimen.
authors.affiliation: First Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Di Filippo
authors.forename: S
authors.initials: S
authors.lastname: Carlini
authors.forename: R
authors.initials: R
authors.lastname: Garinei
authors.forename: P
authors.initials: P
authors.lastname: Perri
authors.forename: M
authors.initials: M
authors.lastname: Anzà
authors.forename: F
authors.initials: F
authors.lastname: Ferranti
authors.forename: E
authors.initials: E
authors.lastname: Saracca
authors.forename: M
authors.initials: M
authors.lastname: Schiratti
authors.forename: F
authors.initials: F
authors.lastname: Cavaliere
authors.forename: R
authors.initials: R
authors.lastname: Cavaliere
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D011379:Prognosis; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
chemical_list: D002945:Cisplatin